Quick Answer
Tempest Therapeutics, Inc. reported Stockholders Equity of $6.67 million for fiscal year 2025.
Tempest Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $6.67M | -65.1% |
| 2024 | $19.13M | -28.5% |
| 2023 | $26.77M | +47.8% |
| 2022 | $18.11M | -49.9% |
| 2021 | $36.12M | +152.5% |
| 2020 | -$68.79M | -36.6% |
| 2019 | -$50.36M | -171.0% |
| 2018 | $70.95M | +154.3% |
| 2017 | -$130.69M | -220.8% |
| 2016 | $108.22M | -14.7% |
| 2015 | $126.85M | +129.3% |
| 2014 | $55.33M | +32.7% |
| 2013 | $41.70M | +35.7% |
| 2012 | $30.72M | +1392.4% |
| 2011 | -$2.38M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.35M | -44.6% | -35.1% |
| June 30, 2025 | $9.78M | -42.2% | -12.1% |
| March 31, 2025 | $11.13M | -46.0% | -41.8% |
| December 31, 2024 | $19.13M | -28.5% | +66.9% |
| September 30, 2024 | $11.46M | +1062.8% | -32.4% |
| June 30, 2024 | $16.94M | +238.0% | -17.9% |
| March 31, 2024 | $20.63M | +88.2% | -22.9% |
| December 31, 2023 | $26.77M | +47.8% | +2349.4% |
- Tempest Therapeutics, Inc. showed a decrease of -65.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Tempest Therapeutics, Inc.’s stockholders equity has grown by 380.5% (from -$2.38 million to $6.67 million).
- The most recent figure is from Tempest Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: